BPMX BioPharmX Corporation. Common

0.55
+0  (11%)
Previous Close 0.50
Open 0.53
Price To book 0.00
Market Cap 37.25M
Shares 67,719,000
Volume 1,517,147
Short Ratio 2.51
Av. Daily Volume 1,000,860

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated in 2017
BPX-03
Moderate to severe periodic breast pain associated with FBC (fibrocystic breast condition) and cyclic mastalgia
Phase 2b completion of enrollment announced January 4, 2017. Data due 2Q 2017.
BPX-01
Acne

Latest News

  1. BIOPHARMX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  2. BioPharmX Reports Fourth Quarter and Full Year 2017 Financial Results
  3. Q4 2017 Biopharmx Corp Earnings Release - After Market Close
  4. BioPharmX Invited to Present at 27th Annual Oppenheimer Healthcare Conference
  5. BioPharmX to Report Fourth Quarter and Full Year Financial Results
  6. BioPharmX Society of Toxicology Poster Suggests Promise of BPX-01 as Topical Acne Therapy, Highlights Safety
  7. BioPharmX to Present at 29th Annual ROTH Conference
  8. BioPharmX Presents Poster at American Academy of Dermatology Annual Meeting Suggesting BPX-01 Safely, Efficiently Delivers Acne-Fighting Minocycline to Pilosebaceous Units
  9. BIOPHARMX CORP Files SEC form 8-K, Change in Directors or Principal Officers
  10. SPIE Photonics West Presentations to Show BioPharmX was First to Visualize Minocycline on the Skin Using Multiphoton Microscopy
  11. BIOPHARMX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
  12. Specialty Pharma Industry Veteran Charles Gregory Vontz Joins BioPharmX Board of Directors
  13. BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel
  14. BioPharmX Completes Enrollment of BPX-01 Phase 2b OPAL Clinical Trial for Acne Vulgaris
  15. BIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  16. BIOPHARMX CORP Financials
  17. BioPharmX (BPMX) Exited Fiscal Third Quarter with Strong Balance Sheet
  18. BIOPHARMX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Of
  19. BioPharmX Corporation Reports Third Quarter Financial Results
  20. ETFs with exposure to BioPharmX Corp. : December 13, 2016